|
1. Biologie
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
|
|
|
Cancer Is Partly Caused By Bad Luck, Study Finds [NPR]
|
|
|
|
|
|
Vogelstein
says parents often think they, somehow, are responsible for their
child's cancer, but that is not the case. "They need to understand that
these cancers would have happened no matter what they did," he says. "We
don't need to add guilt to an already tragic situation."
|
|
|
|
|
|
|
|
|
|
|
Is cancer just a matter of random bad luck? [CNN]
|
|
|
|
|
|
In
a previous research paper published in 2015, Tomasetti and Vogelstein
used a mathematical model to first present this idea that cancer risk is
strongly correlated with the total number of divisions undergone by
normal cells.
|
|
|
|
|
|
|
|
4.10 Dép., diag. & prono. - Poumon
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
5. Traitements
|
|
|
|
|
Major pancreatic cancer study launched [BBC News]
|
|
|
|
|
|
Cancer
Research have invested £10m in the PRECISION-Panc project, which aims
to find quick ways of finding the right treatment for individual
tumours. Researchers at Glasgow University will receive £8m from the
fund.
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
NIH achieves milestone to accelerate multisite clinical studies [NIH]
|
|
|
|
|
|
This
agreement — which now includes a total of more than 150 top medical
research institutions — will enable all participating study sites to
rely on the ethics review of one IRB for each study, making it possible
to initiate multisite studies within weeks instead of months.
|
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
BioLineRx buys Agalimmune to expand cancer pipeline [FierceBiotech]
|
|
|
|
|
|
Agalimmune
has tested the candidate in a preclinical model of melanoma and run
combination studies with a PD-1 checkpoint inhibitor that BioLineRx sees
as suggesting it can broaden the use of such therapeutics while
boosting the rate and duration of the responses they trigger.
|
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
FDA approves first treatment for rare form of skin cancer [FDA]
|
|
|
|
|
|
The
U.S. Food and Drug Administration today granted accelerated approval to
Bavencio (avelumab) for the treatment of adults and pediatric patients
12 years and older with metastatic Merkel cell carcinoma (MCC),
including those who have not received prior chemotherapy. This is the
first FDA-approved treatment for metastatic MCC, a rare, aggressive form
of skin cancer.
|
|
|
|
|
|
|
|
5.9 AACR
|
|
|
|
6.1 Observation
|
|
|
|
6.6 Publications
|
|
|
|